MK-0354

DB05939InvestigationalSmall molecule

MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders. It targets G protein-coupled receptor, or GPCR, that have the potential... It targets G protein-coupled receptor, or GPCR, that have the potential to regulate plasma lipid profiles, including HDL, or the good cholesterol, similar to the therapeutic action of niacin.

Primary indication: Investigated for use/treatment in atherosclerosis.Curator reviewed
Formula / weight: C₇H₈N₆ · 176.183 g/mol (avg)
Code names: MK-0354

Resolves to

Compound

UNII4U62D8JYIQCAS851776-28-8ChEMBLCHEMBL456145

Structure

InChIKeyLTQYSJKGRPGMPO-UHFFFAOYSA-NSMILESC1CC2=C(C1)C(=NN2)C1=NNN=N1

Targets

Q8TDS4HCAR2Q99527GPER1

What you can answer from here — as of April 23, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with MK-0354, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account